

3 May 2016

**ANTICIPATED ACQUISITION OF THE UNITED DRUG DIVISION AND  
OTHER ASSOCIATED BUSINESSES OF UDG HEALTHCARE PLC  
(MASTA AND SANGERS) BY MCKESSON DEUTSCHLAND  
GMBH & CO. KGAA (NOW COMPLETED)**

**Termination of extension of the preliminary assessment period  
mentioned in section 34A(2) of the Enterprise Act 2002 (the Act)  
published pursuant to section 107(1)(ae) of the Act**

On 3 March 2016, the European Commission referred part of the anticipated acquisition by McKesson Deutschland GmbH & Co. KGaA (**McKesson**) of the United Drug Division and Other Associated Businesses of UDG Healthcare Plc (**the Merger**) to the Competition and Markets Authority (**CMA**) under Article 9 of the EC Merger Regulation. Therefore, the preliminary assessment period for the CMA to decide whether to refer the Merger for a phase 2 investigation has commenced under section 34A(2) and (4) of the Act.

On 8 March 2016, the CMA published a notice to extend the preliminary assessment period because McKesson had not complied with a requirement set out in a notice under section 109 of the Act (the Notice) to provide certain information and documents.

The CMA is now satisfied for the purposes of section 34A(6A)(a) of the Act that the information and documents have been provided. This means that the end of the preliminary assessment period is now 6 July 2016.